[go: up one dir, main page]

WO2008058234A3 - Formulations pharmaceutiques pour des composés de 1,4-dihydropyridine ayant une solubilité améliorée - Google Patents

Formulations pharmaceutiques pour des composés de 1,4-dihydropyridine ayant une solubilité améliorée Download PDF

Info

Publication number
WO2008058234A3
WO2008058234A3 PCT/US2007/084068 US2007084068W WO2008058234A3 WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3 US 2007084068 W US2007084068 W US 2007084068W WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihyrdropyridine
compounds
pharmaceutical formulations
improved solubility
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084068
Other languages
English (en)
Other versions
WO2008058234A2 (fr
Inventor
Ashok Tehim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of WO2008058234A2 publication Critical patent/WO2008058234A2/fr
Publication of WO2008058234A3 publication Critical patent/WO2008058234A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne une composition pharmaceutique, comprenant un agent pharmaceutique de 1,4-dihydropyridine, en particulier du (+)-isopropyl-2-méthoxyéthyl-4-(2-chloro-3-cyano-phényl)-1,4-dihydro-2,6-diméthyl-pyridine-3,5-dicarboxylate), un mélange de glycérol et d'esters PEG1500 d'acides gras longs ayant un point de fusion d'approximativement 44°C et un équilibre hydrophile/lipophile d'approximativement 14 (Gelucire 44/14) et un succinate de d-alpha-tocophérylpolyéthylèneglycol 1000 (vitamine E TPGS), et comprenant en outre de manière facultative du polyéthylèneglycol-15-hydroxystéarate (Solutol-HS 15) et/ou de l'huile de ricin de polyoxyle (Crémophore-EL), qui présente des caractéristiques de solubilité améliorées.
PCT/US2007/084068 2006-11-08 2007-11-08 Formulations pharmaceutiques pour des composés de 1,4-dihydropyridine ayant une solubilité améliorée Ceased WO2008058234A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85750406P 2006-11-08 2006-11-08
US60/857,504 2006-11-08

Publications (2)

Publication Number Publication Date
WO2008058234A2 WO2008058234A2 (fr) 2008-05-15
WO2008058234A3 true WO2008058234A3 (fr) 2008-06-26

Family

ID=39365371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084068 Ceased WO2008058234A2 (fr) 2006-11-08 2007-11-08 Formulations pharmaceutiques pour des composés de 1,4-dihydropyridine ayant une solubilité améliorée

Country Status (1)

Country Link
WO (1) WO2008058234A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150064232A (ko) 2007-05-25 2015-06-10 더 유니버시티 오브 브리티쉬 콜롬비아 치료제의 경구 투여를 위한 제제 및 관련 방법
US8795634B2 (en) 2008-09-12 2014-08-05 Critical Pharmaceuticals Limited Absorption of therapeutic agents across mucosal membranes or the skin
WO2011050457A1 (fr) 2009-10-26 2011-05-05 The University Of British Columbia Formulation stabilisée pour administration orale d'agents thérapeutiques et méthodes afférentes
WO2014060855A1 (fr) * 2012-10-16 2014-04-24 Wockhardt Limited Compositions pharmaceutiques de diclofénac ou de sels de celui-ci
CN106689775A (zh) * 2015-11-12 2017-05-24 北京鑫华乐源科技发展有限公司 一种生产富含叶黄素、α-亚麻酸鸡蛋的饲料
WO2019052471A1 (fr) * 2017-09-12 2019-03-21 北京福纳康生物技术有限公司 Composition de fullerène et procédé de préparation et utilisation de cette dernière

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665740A (en) * 1993-12-10 1997-09-09 Bayer Aktiengesellschaft Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate
US6531139B1 (en) * 1997-07-29 2003-03-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665740A (en) * 1993-12-10 1997-09-09 Bayer Aktiengesellschaft Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate
US6531139B1 (en) * 1997-07-29 2003-03-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability

Also Published As

Publication number Publication date
WO2008058234A2 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008058234A3 (fr) Formulations pharmaceutiques pour des composés de 1,4-dihydropyridine ayant une solubilité améliorée
MX373796B (es) Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma.
WO2002067864A3 (fr) Produits de coenzyme q possedant des qualites de dissolution elevees
EP0999826B1 (fr) Formulation autoemulsifiante pour composes lipophiles
WO2005063218A3 (fr) Formulations pharmaceutiques de bisphosphonates
KR102656954B1 (ko) 경구용 탁산 조성물 및 방법
WO2005020962A8 (fr) Forme galenique huileuse auto-nanoemulsifiante pour l'administration de medicaments difficilement hydrosolubles
CO4940469A1 (es) Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
JP2007508296A5 (fr)
ZA200404584B (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability.
US11116744B2 (en) Pharmaceutical composition for oral administration comprising taxane
US20050232952A1 (en) Self emulsifying drug delivery systems for poorly soluble drugs
EP2058010A4 (fr) Composition pharmaceutique
WO2008120711A1 (fr) Préparation de capsules de tamibarotène
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
IL195892A (en) Pre-concentrates in the form of micro-emulsions of new cyclospores analogues
JP2002080399A (ja) ベラパミル誘導体を薬物吸収促進剤として含有する経口用薬物組成物
WO2003000184A3 (fr) Particules de lipoproteines contenant des apolipoproteines b tronquees destinees a l'administration de composes a des tissus ou a des cellules
JP6484393B2 (ja) デュタステリドを含有する医薬組成物及びそれを含むカプセル製剤
TW200609005A (en) Film-coated tablet with plural coating-layers
KR910016332A (ko) 수난용성 약제를 함유하는 약학 조성물
ES2551125T3 (es) Composición antifúngica
JP2002516280A5 (fr)
WO2019081451A1 (fr) Formulations remplies liquides d'inhibiteurs de pde5
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07864098

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07864098

Country of ref document: EP

Kind code of ref document: A2